BCR/ABLlevel at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase-Reference-Cited by-同舟云学术

BCR/ABLlevel at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase

Published:2014-04-10 Issue:6 Volume:89 Page:626-632
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Kim Dennis Dong Hwan¹,Hamad Nada¹,Lee Hong Gi¹,Kamel-Reid Suzanne²,Lipton Jeffrey H.¹

Affiliation:

1. Department of Medical Oncology and Hematology; Princess Margaret Hospital, University Health Network, University of Toronto; Ontario Canada

2. Department of Pathology; Toronto General Hospital, University Health Network, University of Toronto; Ontario Canada

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23707/fullpdf

Reference14 articles.

1. Assessment of BCR-ABL1 Transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors;Marin;J Clin Oncol,2012

2. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML);Hanfstein;Leukemia,2012

3. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10% at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Analysis of molecular response kinetics in the DASISION trial;Hochhaus;Blood (ASH Annual Meeting Abstracts),2011

4. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML);Hanfstein;Leukemia,2012

5. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of Vitamin D₃supplementation with Imatinib in Chronic Phase- Chronic Myeloid Leukaemia: an Exploratory Randomized Controlled Trial;BMJ Open;2023-08

2. MDR1 Haplotypes and G2677T/A Polymorphism Predict Imatinib Response in Tunisian Patients with Chronic Myeloid Leukemia;Journal of Biosciences and Medicines;2022

3. Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors;Current Medicinal Chemistry;2021-10-12

4. Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients;Cancer Management and Research;2021-06

5. CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors;Hematologic Malignancies;2021